Research provides the basis for an additional novel immunotherapy for multiple myeloma patients

By | September 29, 2021
Oncotarget published “Multipeptide stimulated PBMCs generate TEM/TCM for adoptive cell therapy in multiple myeloma” which reported that Multiple Myeloma patients suffer disease relapse due to the development of therapeutic resistance. Increasing evidence suggests that immunotherapeutic strategies can provide durable responses.